Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter Study to Assess the Activity and the Safety of Front-line Ibrutinib Plus Rituximab (IR) in Unfit Patients With Chronic Lymphocytic Leukemia (CLL).

NCT02232386 is registered in ClinicalTrials.gov with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor.

NCT NCT02232386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02232386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter Study to Assess the Activity and the Safety of Front-line Ibrutinib Plus Rituximab (IR) in Unfit Patients With Chronic Lymphocytic Leukemia (CLL).
Lead sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase
Phase 2
Overall status
Completed
Start date
March 2, 2015
Completion date
April 16, 2024
Enrollment
156 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

adult patients, chronic lymphocyte leukemia